According to the results of this study, ICI monotherapy significantly improved progression-free survival (PFS), overall survival (OS), and overall response rate (ORR) in this patient population, leading to the United States Food and Drug Administration (FDA) approval of this agent for metastatic NSCLC patients without driver gene mutations and PD-L1 expression ≥ 50% [6]. Here, CD274 is linked to non-small cell lung carcinoma.